GlaxoSmithKline P.L.C. and Valeant Pharmaceuticals International of Aliso Viejo, Cal., said today that they filed a new drug application with the U.S. Food and Drug Administration and a marketing authorization application with the European Medicines Agency, for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures.    - Miriam Hill

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News